Safety and efficacy of mavacamten for treatment of hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomized clinical trials by Mehrdad Rabiee Rad, Ghazal Ghasempour Dabaghi, Danial Habibi

Subjects: Get full text

Efficacy and safety of Mavacamten for symptomatic Hypertrophic cardiomyopathy – an updated Meta-Analysis of randomized controlled trials by Irfan Ullah, Syeda Tayyaba Rehan, Zayeema Khan, Syed Hasan Shuja, Muhammad Hamza Shuja, Muhammad Irfan, Karthik Gonuguntla, M Chadi Alraies, Pratik Aggarwal, Sameer Raina, Yasar Sattar, Muhammad Sohaib Asghar

Subjects: “…Mavacamten…”
Get full text

Hypertrophic Cardiomyopathy with Special Focus on Mavacamten and Its Future in Cardiology by Ewelina Młynarska, Ewa Radzioch, Bartłomiej Dąbek, Klaudia Leszto, Alicja Witkowska, Witold Czarnik, Weronika Jędraszak, Jacek Rysz, Beata Franczyk

Subjects: Get full text

Future Role of New Negative Inotropic Agents in the Era of Established Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy by Barry J. Maron, Martin S. Maron, Mark V. Sherrid, Ethan J. Rowin

Subjects: Get full text

From amoeboid myosin to unique targeted medicines for a genetic cardiac disease by James A. Spudich

Subjects: Get full text

Assessing the Applicability of Cardiac Myosin Inhibitors for Hypertrophic Cardiomyopathy Management in a Large Single Center Cohort by Ali Amr, Elham Kayvanpour, Christoph Reich, Jan Koelemen, Shamily Asokan, Norbert Frey, Benjamin Meder, Farbod Sedaghat-Hamedani

Subjects: Get full text

Discontinuation of afterload-reducing drugs decreases left ventricular outflow tract obstruction in hypertrophic obstructive cardiomyopathy by Anselm A. Derda, Anselm A. Derda, Malin Abelmann, Malin Abelmann, Kristina Sonnenschein, Kristina Sonnenschein, Jan-Thorben Sieweke, Udo Bavendiek, Johann Bauersachs, Thomas Thum, Dominik Berliner

Subjects: Get full text

Familial Hypertrophic Cardiomyopathy: Diagnosis and Management by Litt MJ, Ali A, Reza N

Subjects: Get full text

Analyzing safety and effectiveness of Mavacamten in comparison with placebo for managing hypertrophic cardiomyopathy: a systemic review and meta-analysis by Hussain Sohail Rangwala, Hareer Fatima, Mirha Ali, Syed Taha Ahmed, Burhanuddin Sohail Rangwala, Syed Raza Abbas

Subjects: Get full text

Eighteen‐Month Real‐World Experience Using Mavacamten for Treatment of Obstructive Hypertrophic Cardiomyopathy in a Racially Diverse Population by Diego Ramonfaur, Alessio Gasperetti, Victoria E. Blake, Bryana Rivers, Ali A. Kassamali, Edward K. Kasper, Lili A. Barouch, Katherine C. Wu, Jose A. Madrazo, Richard T. Carrick

Subjects: Get full text

Exploring contractile protein mechanisms and target medications for cardiomyopathic patients with diastolic dysfunction by Dustin Gerber, Junjun Quan, Bo Pan, Xupei Huang, Jie Tian

Subjects: Get full text

<i>MYBPC3</i> D389V Variant Induces Hypercontractility in Cardiac Organoids by Darshini Desai, Taejeong Song, Rohit R. Singh, Akhil Baby, James McNamara, Lisa C. Green, Pooneh Nabavizadeh, Mark Ericksen, Sholeh Bazrafshan, Sankar Natesan, Sakthivel Sadayappan

Subjects: Get full text

Prospects for remodeling the hypertrophic heart with myosin modulators by Lorenzo R. Sewanan, Yuichi J. Shimada

Subjects: Get full text

Cardiac Myosin Inhibitors as a Novel Treatment Option for Obstructive Hypertrophic Cardiomyopathy: Addressing the Core of the Matter by Ahmad Masri, Iacopo Olivotto

Subjects: Get full text

A Systematic Review and Meta-analysis of Efficacy and Safety of Mavacamten for the Treatment of Hypertrophic Cardiomyopathy by Li Zheng, Xiaotong Gu, Yumiao Chen, Deping Liu

Subjects: Get full text

Efficacy and safety of cardiac myosin inhibitors for symptomatic hypertrophic cardiomyopathy: a meta-analysis of randomized controlled trials by Anas Abunada, Madiha Shah, Ateesh Kumar, Syeda Lamiya Mir, Dinesh Kumar, Saboor Ahmed, Muhammad Tanzeel, Vikash Kumar, Aashish Meghjiani, Muhammad Basit Ali Siddiqui, Govinda Khatri, Aneesh Rai, Fnu Deepak, Ayush Kumar

Subjects: Get full text

Obstructive hypertrophic cardiomyopathy: from genetic insights to a multimodal therapeutic approach with mavacamten, aficamten, and beyond by Khadija Sarwer, Saeeda Lashari, Nida Rafaqat, Maher, Abdul Raheem, Muneeb Ur Rehman, Syed Muhammad Iraj Abbas

Subjects: Get full text

Mavacamten in real‐life practice: Initial experience at a hypertrophic cardiomyopathy centre by Zaid Abood, Muhammad Fuad Jan, Muddasir Ashraf, Stacie Kroboth, Heather Sanders, McKenzie Schweitzer, Amanda Misicka, Emily Ollerman, Arshad Jahangir, Patrycja Galazka, Abdul Jamil Tajik

Subjects: Get full text

An overview of the treatments for hypertrophic cardiomyopathy by Wenna Xu, Fuyu Zhu, Yue Zhang, Peng Li, Peng Li, Yanhui Sheng, Yanhui Sheng

Subjects: Get full text

How effective is disopyramide in treating pediatric hypertrophic cardiomyopathy? State of the art and future directions by Karin Del Vecchio, Caterina Rizzardi, Alice Pozza, Francesco Prati, Luisa Ye, Alessia Fattoretto, Elena Reffo, Giovanni Di Salvo

Subjects: Get full text